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Background: To assess the efficacy of intraoperative ultrasound-guided implantation of 125I seeds for the treatment
of unresectable pancreatic carcinoma, and analyze the associated prognostic factors.
Methods: Twenty-eight patients with pancreatic carcinoma who underwent laparotomy and were considered to
have unresectable tumors were included in this study. Nine patients were pathologically diagnosed with Stage II
disease, and nineteen patients with Stage III disease. Twenty-eight patients received intraoperative ultrasound-guided
125I seed implantation and received a D90 (at least 90% of the tumor volume received the reference dose) ranging from
60 to 163 Gy, with a median of 120 Gy. Seven patients received an additional 35–50 Gy external beam radiotherapy
after seed implantation, and ten patients received two to ten cycles of chemotherapy. Overall survival of the patients
was calculated and prognostic factors were evaluated.
Results: Of the patients, 94.1% (16/17) achieved good to medium pain relief. The tumor response rate was 78.6%
(22/28), and local control was achieved in 85.7% (24/28) of patients. The 1-, 2- and 3-year survival rates were 30%, 11%
and 4%, and the median survival was 10.1 months (95% CI: 9.0-10.9). Analysis using the Cox proportional hazards model
suggested that patients younger than 60 years and patients who received a D90 higher than 110 Gy may survive for a
longer period.
Conclusions: I seed implantation provides a safe and effective method to relieve pain, control local tumor growth and,
to some extent, prolong the survival of patients with stage II and III pancreatic disease, without additional
complications. Age and accumulated dose may be factors predictive of a favorable outcome for patients with
unresectable pancreatic carcinoma treated with 125I seeds. These findings need to be validated by conducting further
studies with larger cohorts.
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Pancreatic carcinoma is the tenth most common malig-
nant tumor, but is the fourth most common cause of
cancer-related deaths worldwide [1]. Less than 20% of
pancreatic carcinoma patients are suitable for surgical re-
section, the majority of cases of pancreatic carcinoma are
diagnosed at the locally advanced or metastatic stage. The
median survival of locally advanced or metastatic disease
is approximately 6 months with palliative treatment. But* Correspondence: junjiewang_edu@sina.cn
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reproduction in any medium, provided the oreven the tumors are resected, long term survival still re-
mains poor [2,3].
Pancreatic carcinoma survival rates have shown little
improvement over the past 30 years. Despite the intro-
duction of new therapeutic techniques combined with
aggressive modalities, such as external beam radiotherapy
(EBRT), intraoperative radiotherapy (IORT) and chemo-
therapy, the prognosis for patients with pancreatic carcin-
oma remains unsatisfactory, with a 5-year survival rate
less than 6% [1]. At present, National Comprehensive
Cancer Network guidelines recommend treatments in-
cluding gemcitabine- and capecitabine-based chemother-
apy or concurrent chemoradiation for patients with goodtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of patient characteristics (n = 28)










pT4N0-1 M0 19 68
Primary tumor location
Head 15 54
Body and/or tail 11 39




Weight loss 26 93
Pathology
Adenocarcinoma 28 100
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9.2-11.0 months [4]. Once, IORT was expected to improve
the long-term survival of pancreatic cancer patients, while
clinical results were not satisfactory [5,6].
Currently, there is no consensus regarding the best
therapeutic modality for unresectable pancreatic carcin-
oma. It is necessary to investigate novel techniques that
may improve patient outcome. Wang et al. were the first
group to investigate the use of intraoperative ultrasound-
guided 125I seed implantation as a new technique for man-
aging unresectable pancreatic carcinoma, and demonstrated
that the technique was feasible and safe [7]. In this study,
we confirmed the efficacy of 125I seed implantation, and an-




Between October 2003 and August 2012, twenty eight pa-
tients with a Karnofsky performance status (KPS) score of
70 or above were identified. Of these twenty eight pa-
tients, 39% (10/28) had jaundice, 60% (17/28) suffered
pain, 11% (3/28) had intestinal obstruction and 93% (26/
28) experienced weight loss. These patients were diag-
nosed with unresectable pancreatic carcinoma by sur-
geons carrying out a laparotomy, and received 125I seed
implantation guided by intraoperative ultrasound. The cri-
teria of unresectable disease included vascular invasion, or
vascular invasion combined with metastasis to the local
regional lymph nodes. Of the twenty eight pancreatic car-
cinoma patients, nine were diagnosed with stage II disease,
and nineteen patients had stage III disease. Summaries of
the patients’ characteristics are listed in Table 1, Additional
file 1: Table S1 and Additional file 2; Table S2. Five of the
patients with jaundice received a biliary stent one month
before 125I seed implantation. All patients were evaluated
for the extent of disease progression by physical examin-
ation, complete blood panel, chest X-ray, abdominal CT
scans and ultrasound prior to seed implantation. This
study was approved by the institutional review board and
informed consent was obtained from all patients. Institu-
tional Review Board: Peking University Third Hospital
Medical Science Research Ethics Committee.
Treatment planning protocol
Computerized tomography (CT) scans were taken 1–2
weeks before seed implantation to evaluate detailed tumor
location and volume of patients. Images of pancreatic car-
cinomas were obtained at 5 mm intervals. The gross tumor
volume (GTV) was outlined by radiation oncologists and
surgeons on each image in consultation with one another.
The planning target volume (PTV) included GTV plus
0.5-1.0 cm peripheral tissue. These traces were digitized
and scanned to define the tumor volume, from which theD90 of 60–163 Gy (median 120 Gy) for
125I seed irradiation
could be calculated. Then the system figured out the re-
quired number of 125I seeds to be implanted. The D90 was
defined that at least 90% of the tumor volume received the
reference dose (Figure 1). The 125I seeds (Beijing Atom and
High Technique Industries Inc, Beijing, Model-6711) had a
half-life of 59.4 days with a low energy level of 27.4 KeV
and a half-value layer of 0.025 mm of lead. A computerized
treatment planning system (Beijing Fei Tian Technique In-
dustries Inc, Beijing, China) was used for dose calculations.
Ultrasound-guided seed implantation
Following collection of an intraoperative biopsy to estab-
lish the diagnosis of pancreatic cancer, tumor volume
was measured during laparotomy by intraoperative ultra-
sonography utilizing a megahertz linear probe. Guided
by ultrasound, 18-gauge needles were implanted into the
mass and spaced at intervals of 1.0 cm in a parallel array,
extending at least 0.5-1.0 cm beyond the margins of the
pancreatic lesions. During the placement of the needles,
care was taken to avoid the needles penetrating the pancre-
atic duct, small blood vessels, and the adjacent transverse
colon by ensuring placement at least 1 cm from these tis-
sues. 125I seeds were implanted using a Mick applicator fol-
lowing insertion of the needles, and the spacing for seeds
in the same needle is 1 cm [7]. The number of 125I seeds
implanted ranged from ten to seventy five; the median
Figure 1 CT image and dose distribution curves of a typical patient. Male, 63 years old, stage III, T4N0M0. The green line is the isodose
curve for 110 Gy.
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ranged from 0.40 to 0.60 mCi per seed, and the total iso-
tope radioactivity implanted ranged from 4 to 37.5 mCi.
An omental fat pad was placed over the implanted volume
to protect the gastric and transverse colon mucosa from
excessive irradiation.
Adjuvant therapy after initial treatment
EBRT was generally recommended for all patients as an
adjuvant therapy, but only seven patients received EBRT
4–6 weeks after 125I seed implantation. The total dose of
EBRT ranged from 35 to 50 Gy at 1.8-2.0 Gy per frac-
tion. Postoperative chemotherapy was recommended for
all patients on an adjuvant or palliative basis, but only
ten patients received chemotherapy consisting of gemci-
tabine or paclitaxel and completed two to six cycles. The
remaining patients refused EBRT or chemotherapy fol-
lowing seed implantation.
Definition of tumor response
Tumor response was assessed using WHO criteria [8]. In
brief, a complete response (CR) was defined as the com-
plete disappearance of all measurable lesions, without the
appearance of any new lesion(s). A partial response (PR)
was defined as a reduction in bidimensionally measurable
lesions by at least fifty percent of the sum of the products
of their largest perpendicular diameters, and an absence of
progression in other lesions, without the appearance of any
new lesion(s). Stable disease (SD) was defined as a reduc-
tion in tumor volume of less than fifty percent or an in-
crease in the volume of one or more measurable lesions ofless than twenty five percent, without the appearance of
any new lesion(s). Progressive disease (PD) was defined as
an increase in the tumor volume by at least twenty five per-
cent and the appearance of any new lesion(s). The response
rate was equal to the CR + PR.
Pain evaluation and definition of treatment response
Pain is one of the most common clinical symptoms of
pancreatic carcinoma. Pain intensity was evaluated and
graded by the Numerical Rating Scale (NRS). NRS score
1–3 was defined as mild pain, NRS score 4–6 was de-
fined as moderate pain and NRS score 7–10 was defined
as severe pain [9]. A good response was defined as severe
or moderate pain decreasing to no pain post-treatment,
and a medium response was regarded as severe or moder-
ate pain reducing to mild pain after treatment, with pain-
free sleep and maintenance of a normal lifestyle. A poor
response meant that there was no change in the severity
of pain, compared with pre-seed implantation.
Patient follow-up
Patients were evaluated by radiation oncologists and sur-
geons one month after seed implantation. Regular items
included physical examination, complete blood panel,
chest X-ray, abdominal CTand ultrasound. Then, a clinical
consultation was provided, followed by evaluation every
2–3 months or sooner if a new clinical sign or symptom
appeared. Survival was calculated from the date of diagno-
sis to the date of death, or last follow-up. Local recurrence
was defined as tumor progression within the implanted
area or surrounding regions according to CT images. Local
Figure 3 Actuarial survival curve for twenty eight patients.
Patients with unresectable stage II/III pancreatic carcinoma were
treated with 125I seed implantation.
Wang et al. Journal of Experimental & Clinical Cancer Research 2013, 32:106 Page 4 of 8
http://www.jeccr.com/content/32/1/106recurrence and distant metastases were scored until pa-
tient death, and censored thereafter.
Statistical analyses
Overall survival rates were estimated using the Kaplan-
Meier method, and deaths for any reason were scored as
events. The impact of different factors on the survival
curves was analyzed using the log-rank test and Cox pro-
portional hazards model, that were frequently used in sin-
gle factor analysis and multiple factor analysis. SPSS
version 16.0 was used for statistical analysis, with the level
of significance defined as a p value of <0.05.
Results
Tumor local control and patients’ survival
In our study, the tumor response rate was 78.6%, with an
overall local control rate of 85.7% (24/28) (Figure 2). The
Kaplan-Meier actuarial survival curve for all twenty eight
patients treated with seed implantation is shown in Figure 3.
The overall 1-, 2- and 3-year survival rates were 30%, 11%
and 4%, respectively. The overall median survival time was
10.1 months (95% CI, 9.0-10.9). Twenty two patients died
of metastases to the liver and peritoneal surface, yet had no
imaging evidence of any residual local disease. Two patients
died of local progression, two patients died of local progres-
sion and metastases, one patient died of heart disease, and
one patient was still alive at last follow-up.
Pain relief
Pain is one of the most common clinical symptoms of
pancreatic carcinoma. 60% (17/28) of patients were suf-
fering pain prior to treatment, and 94.1% (16/17) of pa-
tients achieved a good or medium response after 125IFigure 2 Actuarial local control curve for twenty eight patients.
Patients with unresectable stage II/III pancreatic carcinoma were
treated with 125I seed implantation.seed implantation. Almost half of the patients (47%, 8/17)
achieved good response. Three patients suffering severe
pain and five patients with moderate pain were all re-
ported no pain after treatment. An additional 47% (8/17)
of patients achieved medium response. Six patients with
severe pain and one patient with moderate pain were re-
ported only mild pain following treatment. Only one pa-
tient continued to suffer moderate pain after treatment.
The majority of patients experienced some relief from
pain within one week following seed implantation.
Toxicity and complications
There were few toxicity and complications, and no pa-
tients died during the perioperative period. Chylous fis-
tula was observed in one patient (4%). Gastric ulcer was
observed in one patient (4%) who underwent seed implant-
ation and EBRT. Two patients (7%) experienced radiation
enteritis and ten patients (36%) experienced transient fever.
In addition, in each of two (7%) patients, three seeds were
found to have migrated to the liver. However, no side ef-
fects were observed in the 12 months post-treatment.
Prognostic factors
Multiple factors that may affect overall survival were an-
alyzed. Log-rank single factor analysis suggested that pa-
tients who actually received a D90 higher than 110 Gy
(calculated after seed implantation), and patients younger
than 60 years may survive longer. The median survival of
patients who actually received a D90 higher or lower than
110 Gy was 11 months (95% CI: 9.3-12.6) and 8 months
(95% CI: 3.9-12.0), respectively, p < 0.001. The median sur-
vival of patients younger than 60 years was 10 months
(95% CI: 8.0-11.9), compared with 9 months (95% CI: 8.0-
9.9) for patients over 60 years old (p = 0.035). The outcome
Wang et al. Journal of Experimental & Clinical Cancer Research 2013, 32:106 Page 5 of 8
http://www.jeccr.com/content/32/1/106of patients with pancreatic carcinoma in the head of the
pancreas and jaundice may be poor. The median survival
time of patients with cancer in the head of the pancreas
was 9 months (95% CI: 8.3-9.7) compared with 11 months
(95% CI: 9.3-12.6) for patients whose tumor was situated
outside of the head of the pancreas (p = 0.15). The median
survival of patients with and without jaundice was 9
months (95% CI: 8.3-9.6) and 11 months (95% CI: 9.4-
12.5), respectively (p = 0.09). Patients who achieved CR and
received adjuvant EBRT may survive longer. However add-
itional patients should be enrolled to verify these observa-
tions. The median survival of patients achieving CR or not
was 24 months (95% CI: 7.9-40.0) and 9 months (95% CI:
8.0-9.9), respectively (p = 0.05). However, only three pa-
tients achieved CR, with overall survival of 14, 24 and 28
months, respectively. The median survival of patients re-
ceiving adjuvant EBRT or not was 13 months (95% CI:
8.3-17.6) and 10 months (95% CI: 9.0-10.9), respectively
(p = 0.24). However, only seven patients received adjuvant
EBRT, and six of these patients were younger than 60
years. Gender, adjuvant chemotherapy, tumor volume and
CA199 level before and after the operation did not impact
the clinical outcome (p > 0.05). The result of the Cox pro-
portional hazards model suggested that a D90 higher than
110 Gy was an independent, favorable prognostic factor
comparing with lower than 110 Gy (p = 0.001), and the
relative risk ratio was 0.21 (95% CI: 0.08-0.57). The fitted
curve is shown in Figure 4. Patient age younger than 60
years was another independent, favorable prognostic factorFigure 4 A D90 higher than 110 Gy is a favorable prognostic factor. P
with 125I seed implantation. The blue line is for the group whose doses we
were lower than 110 Gy. A. Overall survival rate curves for the two groups.comparing with older than 60 years (p = 0.002), and the
relative risk ratio was 0.34 (95% CI: 0.13-0.91). The fitted
curve is shown in Figure 5.
Discussion
Pancreatic cancer has an appalling prognosis, especially for
patients with unresectable tumors at the time of diagnosis,
which represents more than 80% of patients. Therefore the
treatment of unresectable pancreatic cancer continues to
be a major challenge. In approximately 30% of patients
with unresectable tumors, the lesions remain locally ad-
vanced without evidence of distant metastases at autopsy
[10]. Therefore, localized treatments are extremely import-
ant for tumors that are locally or regionally confined. A re-
cent systematic review once again concluded that surgery
was not an optimal choice for these patients, as morbidity
and mortality rates increased after R2 resection, with
pooled median survival time of only 8.2 months [11].
Radiotherapy is recommended to prolong overall survival,
and improve local disease and symptom control [12].
Radiation techniques such as three-dimensional con-
formal radiotherapy, intensity-modulated radiotherapy
(IMRT), stereotactic body radiation therapy (SBRT), in-
traoperative radiation therapy, and low-dose rate (LDR)
or high-dose rate (HDR) radiation have all been used in the
treatment of locally advanced pancreatic cancer. However,
the clinical outcomes are unsatisfactory. There is evidence
that common external beam radiation with or without
chemotherapy can achieve a median survival time of 8.2-atients with unresectable stage II/III pancreatic carcinoma were treated
re higher than 110 Gy. The green line is for the group whose doses
B. Hazard function curves for the two groups.
A B
Figure 5 Age younger than 60 years is a favorable prognostic factor. Patients with unresectable stage II/III pancreatic carcinoma were
treated with 125I seed implantation. The blue line is for the group whose ages were younger than 60 years. The green line is for the group whose
doses were older than 60 years. A. Overall survival rate curves for the two groups. B. Hazard function curves for the two groups.
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plications between 10% and 25% [13-16]. The potential
benefits of SBRT alone are still controversial, due to poor
patient outcome, unacceptable toxicity and questionable
palliative effects. Hoyer et al. reported the results of a Phase
II study using SBRT in the treatment of locally advanced
pancreatic carcinoma, in which the median survival time
was only 5.7 months, with 18% of patients suffering from
severe mucositis or ulceration of the stomach or duodenum
[17]. Recently, there have been reports suggesting that
SBRT and chemotherapy might be a useful treatment
option, resulting in a median survival time of 10.6-14.3
months with acceptable complications [18-20]. Additional
reports suggest that IORT can be used to prevent local re-
currence after resection or to control abdominal pain.
However, the median survival time was 7.1-10.5 months
[21,22]. Disappointingly, the combined use of IORT and
EBRT also failed to significantly improve long-term sur-
vival, with a median survival time of only 7.8-11.1 months
[5,6]. A report of interstitial iridium-192 HDR brachyther-
apy for the treatment of unresectable pancreatic carcin-
oma found a median survival time of 6.5 months for stage
II/III in the absence of severe, acute side effects [23].
Recent years, there were some basic research indicated
that 125I seed continuous low dose rate irradiation may be
beneficial to pancreatic carcinoma. Wang et al. reported
that 125I seeds irradiation could induce higher apoptotic
rates of PANC-1 pancreatic cancer cells, which led to pro-
grammed cell death [24]. Ma et al. reported that 125I seed
continuous low dose rate irradiation inhibited pancreatic
cancer tumor growth and changed DNA methyltransferases
expression patterns [25]. Gao et al. found aberrant DNA
methyltransferase expression in pancreatic ductal adenocar-
cinoma tissue, which maybe promoted tumor developmentand progression [26]. Similar biological effects were found
in gastric and rectal cancer cell lines [27,28]. Basic research
provided evidences for 125I seed continuous low dose rate
irradiation from beach to bedside.
The advantage of permanent interstitial radioactive
seed implantation into the tumor site is the ability to de-
liver a high dose of irradiation to the tumor while min-
imizing relative exposure to the surrounding area. In
some medical centers who have skillful surgeons, radi-
ation oncologists and license of 125I seed implantation,
intraoperative ultrasound-guided implantation of 125I
seeds for unresectable pancreatic carcinoma is feasible
and safety, especially for those centers who do not have
IORT equipment. 125I seeds were selected as the radio-
active source, due to the half-life of the isotope of 59.4
days [29]. The technique of implanting radioactive iso-
topes to treat pancreatic carcinoma has been used for
several decades. Handley first reported the treatment of
seven cases of pancreatic cancer using radium needle
implantation in 1934 [30]. Hilaris, a pioneer in the de-
velopment of 125I seed implantation for the treatment of
pancreatic carcinoma, enrolled ninety eight patients, and
achieved a median survival time of 7 months in 1975
[31], with one patient surviving for five years. Morrow
et al. concluded that there was no difference in survival
between interstitial brachytherapy and surgical resection
at the same institution [32]. These results indicated that
overall survival following 125I seed implantation was com-
parable with other techniques in patients with locally
advanced pancreatic carcinoma [33]. Wang et al. first re-
ported on the use of the novel technique of intraoperative
ultrasound-guided 125I seed implantation to manage unre-
sectable pancreatic carcinoma, and demonstrated that it
was a feasible and safe technique [7]. Our study expands
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and lack of complications associated with this technique.
The tumor response rate was 78.6%, with an overall local
control rate of 85.7% (24/28) in our cohort of patients.
The overall median survival time was 10.1 months, while
the overall 1-, 2- and 3-year survival rates were 30%, 11%
and 4%, respectively. Ninety four percent (16/17) of pa-
tients achieved good or medium relief from pain. These
data were all comparable with, or better than, the results
of surgery and other radiotherapy techniques [29-33].
The limitation of permanent interstitial radioactive
seed implantation in pancreatic cancer is the high
rate of perioperative morbidity and mortality, since
most of the earlier radioactive seed implantation
techniques were performed by eye during surgery. In
a previous study using eye guided implantation, the
perioperative mortality rate was 16% to 25% due to
acute pancreatitis, fistulization, and abscess forma-
tion [34]. Probable reasons for the high mortality
may be the high incidence of penetration into the
pancreatic duct, small blood vessels in the pancreas
and/or adjacent organs. Wang et al. reported that
under the guidance of ultrasound, the incidence of
collateral damage decreased, no perioperative mortal-
ity was observed, and no grade III to IV complica-
tions were reported [7]. In this study, we confirmed
that there were no operation-associated mortalities
or grade III to IV complications. Only one patient
suffered from chylous fistula, one patient suffered
from gastritis, two patients suffered from radiation
enteritis and ten patients suffered from low fever,
which is lower than the incidence of complications
reported in the published data of surgery and radio-
therapy [34].
The data indicate that younger patients with good per-
formance status, or treatment with gemcitabine- or
capecitabine-based chemotherapy were favorable prog-
nostic factors [35-38]. Multiple factors were analyzed
using the log-rank single factor model, and the data sug-
gested that patients who actually received a D90 higher
than 110 Gy and patients younger than 60 years may
survive longer (p < 0.05). The outcome of patients with
pancreatic carcinoma in the head of the pancreas or who
have jaundice may be poor. However, additional patients
should be observed to confirm these findings. Gender, ad-
juvant chemotherapy, tumor volume and CA199 level be-
fore and after the operation did not impact the clinical
outcome (p > 0.05). Multivariate analysis suggested that a
D90 higher than 110 Gy and an age younger than 60 years
were independent, favorable prognostic factors with a
relative risk ratio of 0.21 and 0.34, respectively. Therefore,
we recommend that the optimal dose for 125I seed im-
plantation in patients with unresectable pancreatic cancer
is at least 110 Gy.Conclusions
Intraoperative ultrasound-guided permanent 125I seed im-
plantation is a safe, effective radiation technique for the
treatment of unresectable pancreatic cancer. The technique
provides satisfactory distribution of seeds within the tumor
mass and achieves favorable clinical outcomes with accept-
able complications. Additional studies with larger patient
cohorts are now required in order to verify these results.
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